Safety and efficacy of tirapazamine (TPZ) combined with cyclophosphamide (C) and doxorubicin (D) in rhabdomyosarcoma (RMS) at first relapse/disease progression

10035 Background: Patients with RMS in first relapse/disease progression have a poor prognosis. TPZ, a hypoxic cell toxin, has been shown to enhance activity of traditional cytotoxic chemotherapy. Methods: Eligible patients comprised those with biopsy proven RMS, 5days, and any ≥ Grade 3 vomiting, stomatitis, cardiotoxicity or other non-hematopoietic toxicity. Post-recurrence survival was t...